Valuation: Beam Therapeutics Inc.

Market Cap 2.65B 2.32B 2.16B 1.98B 3.73B 256B 3.79B 25.7B 10.06B 125B 9.95B 9.74B 433B P/E 2026 *
-6.13x
P/E 2027 * -5.87x
Enterprise Value 1.8B 1.57B 1.46B 1.34B 2.53B 173B 2.57B 17.41B 6.82B 84.85B 6.75B 6.6B 293B EV / Sales 2026 *
22.8x
EV / Sales 2027 * 15.4x
Free-Float
98.6%
Yield 2026 *
-
Yield 2027 * -
1 day-2.38%
1 week-13.62%
Current month-22.38%
1 month-25.02%
3 months-15.94%
6 months-22.24%
Current year-3.90%
1 week 26.1
Extreme 26.1
28.51
1 month 26.1
Extreme 26.1
38.26
Current year 21.63
Extreme 21.63
38.26
1 year 15.6
Extreme 15.6
38.26
3 years 13.52
Extreme 13.525
49.5
5 years 13.52
Extreme 13.525
116.91
10 years 13
Extreme 13
138.52
Manager TitleAgeSince
Chief Executive Officer 48 31/12/2016
President 57 23/01/2020
Director of Finance/CFO 48 18/12/2024
Director TitleAgeSince
Director/Board Member 48 31/12/2016
Director/Board Member 75 30/04/2018
Director/Board Member 56 09/10/2019
Date Insider Type Main position Quantity % Market Cap.
30/06/26 Fiscal year

Chief Executive Officer

75,000 0.0729%
30/06/26 Sell

Chief Technology Officer

-373 0.0004%
26/06/26
F-Prime Inc.
SellCompany -251,488 0.2444%
Change 5-day change 1-year change 3-year change Capi.($)
-2.38%-13.62%+23.68%-16.93% 2.65B
+1.12%-5.81%-5.05%+11.60% 46.06B
-0.14%-0.76%+378.26%+583.71% 38.91B
+0.39%+2.79%+8.23%+61.99% 35.57B
-1.54%-4.01%+5.95%-13.03% 33.13B
-0.87%-3.19%-1.27%+29.16% 26.42B
-1.28%-6.20% - - 16.61B
-0.67%-0.21%+10.55%+115.31% 15.08B
-5.85%-4.35%+4.92%+8.63% 14.08B
+0.40%-2.79%+3.58%-31.98% 12.81B
Average -1.08%-3.39%+47.65%+83.16% 24.13B
Weighted average by Cap. -0.53%-2.72%+68.00%+121.03%

Financials

2026 *2027 *
Net sales 78.87M 69.11M 64.15M 58.95M 111M 7.61B 113M 764M 299M 3.72B 296M 290M 12.86B 96.07M 84.18M 78.15M 71.81M 135M 9.27B 137M 931M 364M 4.54B 361M 353M 15.67B
Net income -461M -404M -375M -345M -649M -44.49B -659M -4.47B -1.75B -21.77B -1.73B -1.69B -75.21B -521M -456M -424M -389M -733M -50.25B -744M -5.05B -1.98B -24.59B -1.95B -1.91B -84.94B
Net Debt -855M -749M -695M -639M -1.2B -82.46B -1.22B -8.28B -3.24B -40.35B -3.21B -3.14B -139B -1.17B -1.03B -953M -876M -1.65B -113B -1.67B -11.36B -4.44B -55.33B -4.4B -4.3B -191B
Logo Beam Therapeutics Inc.
Beam Therapeutics Inc. is a biotechnology company developing precision genetic medicines through base editing. The Company's suite of gene editing technologies is anchored by base editing, a technology that is designed to enable precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the deoxyribonucleic acid. Its lead programs are focused on sickle cell disease and alpha-1 antitrypsin deficiency, and it is also advancing programs in other genetic diseases. Its primary programs include BEAM-101, Engineered Stem Cell Antibody Paired Evasion (ESCAPE), BEAM-302 and BEAM-301. BEAM-101 is a patient-specific, autologous hematopoietic stem cell (HSC), investigational therapy. ESCAPE is a potentially non-genotoxic approach to HSC transplantation. BEAM-302 is a liver-targeting lipid nanoparticle formulation of base editing reagents designed to offer a one-time treatment to correct the E342K point mutation (PiZZ genotype).
Employees
522
Date Price Change Volume
22/07/26 US$26.64 -2.38% 1,545,437
21/07/26 US$27.29 +3.65% 1,854,704
20/07/26 US$26.33 -4.36% 2,767,990
17/07/26 US$27.53 -3.03% 1,912,917
16/07/26 US$28.39 -7.94% 4,194,497
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
26.64USD
Average target price
52.31USD
Spread / Average Target
+96.35%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. BEAM Stock